AU2020324408B2 - Degraders of cyclin-dependent kinase 7 (CDK7) and uses thereof - Google Patents

Degraders of cyclin-dependent kinase 7 (CDK7) and uses thereof

Info

Publication number
AU2020324408B2
AU2020324408B2 AU2020324408A AU2020324408A AU2020324408B2 AU 2020324408 B2 AU2020324408 B2 AU 2020324408B2 AU 2020324408 A AU2020324408 A AU 2020324408A AU 2020324408 A AU2020324408 A AU 2020324408A AU 2020324408 B2 AU2020324408 B2 AU 2020324408B2
Authority
AU
Australia
Prior art keywords
optionally substituted
compound
cancer
pharmaceutically acceptable
degron
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020324408A
Other languages
English (en)
Other versions
AU2020324408A1 (en
Inventor
Guangyan DU
Nathanael S. Gray
Zhixiang HE
Jie Jiang
Nicholas KWIATKOWSKI
Tinghu Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of AU2020324408A1 publication Critical patent/AU2020324408A1/en
Application granted granted Critical
Publication of AU2020324408B2 publication Critical patent/AU2020324408B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2020324408A 2019-08-05 2020-08-04 Degraders of cyclin-dependent kinase 7 (CDK7) and uses thereof Active AU2020324408B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962882958P 2019-08-05 2019-08-05
US62/882,958 2019-08-05
PCT/US2020/044815 WO2021026109A1 (en) 2019-08-05 2020-08-04 Degraders of cyclin-dependent kinase 7 (cdk7) and uses thereof

Publications (2)

Publication Number Publication Date
AU2020324408A1 AU2020324408A1 (en) 2021-12-16
AU2020324408B2 true AU2020324408B2 (en) 2026-03-12

Family

ID=74503218

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020324408A Active AU2020324408B2 (en) 2019-08-05 2020-08-04 Degraders of cyclin-dependent kinase 7 (CDK7) and uses thereof

Country Status (8)

Country Link
US (1) US12491251B2 (enExample)
EP (1) EP4010336B1 (enExample)
JP (1) JP7636388B2 (enExample)
CN (1) CN114174281B (enExample)
AU (1) AU2020324408B2 (enExample)
CA (1) CA3149374A1 (enExample)
ES (1) ES3031581T3 (enExample)
WO (1) WO2021026109A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10870651B2 (en) 2014-12-23 2020-12-22 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
CN107427521B (zh) 2015-03-27 2021-08-03 达纳-法伯癌症研究所股份有限公司 细胞周期蛋白依赖性激酶的抑制剂
EP3810132A4 (en) 2018-06-25 2022-06-22 Dana-Farber Cancer Institute, Inc. TAIRE FAMILY KINASE INHIBITORS AND RELATED USES
CN113164477A (zh) 2018-12-14 2021-07-23 达纳-法伯癌症研究所股份有限公司 C-jun-n-末端激酶的吡唑并吡啶抑制剂及其用途
EP3902542A4 (en) 2018-12-28 2022-09-07 Dana-Farber Cancer Institute, Inc. CYCLIN DEPENDENT KINASE 7 INHIBITORS AND USES THEREOF
CA3166135A1 (en) * 2019-12-24 2021-07-01 Dana-Farber Cancer Institute, Inc. The combination of cyclin dependent kinase 7 inhibitor and immunotherapy for treatment of cancer
CN117242060B (zh) 2021-01-13 2026-07-17 蒙特罗莎治疗股份有限公司 异吲哚啉酮化合物
CA3217792A1 (en) 2021-05-07 2022-11-10 Kymera Therapeutics, Inc Cdk2 degraders and uses thereof
CN113234081A (zh) * 2021-05-27 2021-08-10 东南大学 一种吡咯并吡唑衍生物与dmpeda做脲的制备方法
WO2022248682A1 (en) * 2021-05-28 2022-12-01 Qurient Co., Ltd. Compounds for degradation of cyclin-dependent kinase 7 (cdk7)
CN116396295A (zh) * 2023-04-04 2023-07-07 合肥工业大学 一种基于protac的plk1降解剂的合成方法
WO2025252190A1 (en) * 2024-06-07 2025-12-11 Cullgen Inc. Targeted degraders of werner syndrome recq helicase
CN119119072B (zh) * 2024-08-23 2025-10-03 武汉大学 一种用于检测和降解ERα的诊疗一体化ERαPROTACs化合物及其制备方法与应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180186818A1 (en) * 2015-06-15 2018-07-05 Ube Industries, Ltd. Substituted dihydropyrrolopyrazole derivative
US20190055248A1 (en) * 2014-12-23 2019-02-21 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclindependent kinase 7 (cdk7)
US20190076539A1 (en) * 2016-05-10 2019-03-14 C4 Theraprutics, Inc. Amine-linked c3-glutarimide degronimers for target protein degradation

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2416527C (en) 2000-08-10 2009-12-22 Pharmacia Italia S.P.A. Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US9345705B2 (en) 2011-09-15 2016-05-24 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer
WO2013070688A1 (en) 2011-11-11 2013-05-16 Yale University Reprogramming urokinase into an antibody-recruiting anticancer agent
KR102438072B1 (ko) 2012-01-12 2022-08-31 예일 유니버시티 E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법
AU2016232705C1 (en) * 2015-03-18 2021-06-17 Arvinas, Inc. Compounds and methods for the enhanced degradation of targeted proteins
BR112018008918A8 (pt) 2015-11-02 2019-02-26 Univ Yale compostos de quimera proteólise dirigida e métodos para preparação e uso dos mesmos
AU2017254702B2 (en) 2016-04-22 2020-12-24 Dana-Farber Cancer Institute, Inc. Degradation of cyclin-dependent kinase 9 (CDK9) by conjugation of CDK9 inhibitors with E3 ligase ligand and methods of use
CA3045037A1 (en) * 2016-12-08 2018-06-14 Icahn School Of Medicine At Mount Sinai Compositions and methods for treating cdk4/6-mediated cancer
CN109516989B (zh) 2017-09-17 2021-12-31 上海美志医药科技有限公司 一类抑制并降解cdk的化合物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190055248A1 (en) * 2014-12-23 2019-02-21 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclindependent kinase 7 (cdk7)
US20180186818A1 (en) * 2015-06-15 2018-07-05 Ube Industries, Ltd. Substituted dihydropyrrolopyrazole derivative
US20190076539A1 (en) * 2016-05-10 2019-03-14 C4 Theraprutics, Inc. Amine-linked c3-glutarimide degronimers for target protein degradation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
OLSON ET AL., CELL CHEM. BIOL., vol. 26, no. 6, 2019, pages 792 - 803 *

Also Published As

Publication number Publication date
US12491251B2 (en) 2025-12-09
US20220280649A1 (en) 2022-09-08
CN114174281B (zh) 2025-02-07
JP2022543231A (ja) 2022-10-11
JP7636388B2 (ja) 2025-02-26
CA3149374A1 (en) 2021-02-11
WO2021026109A1 (en) 2021-02-11
CN114174281A (zh) 2022-03-11
EP4010336B1 (en) 2025-04-02
EP4010336A1 (en) 2022-06-15
AU2020324408A1 (en) 2021-12-16
ES3031581T3 (en) 2025-07-09
EP4010336A4 (en) 2023-08-23

Similar Documents

Publication Publication Date Title
EP4010336B1 (en) Degraders of cyclin-dependent kinase 7 (cdk7) and uses thereof
US12110292B2 (en) Ligands to cereblon (CRBN)
EP4034132B1 (en) Erk5 degraders as therapeutics in cancer and inflammatory diseases
AU2019293235B2 (en) Immunomodulatory compounds
JP2019510810A (ja) インドールアミン−２，３−ジオキシゲナーゼ（ｉｄｏ）阻害剤
HK1225383A1 (zh) 二氮杂环庚烷衍生物及其用途
HK1224140A1 (zh) 转录因子抑制剂及其用途
JP2025098013A (ja) がん幹細胞を標的化するがん治療
HK1256417A1 (zh) 氰基噻吩并三唑并二氮杂环庚三烯及其用途
CN113557017A (zh) 细胞周期蛋白依赖性激酶7的抑制剂及其用途
AU2021251690B2 (en) Arginine methyltransferase 5 (PRMT5) degraders and uses thereof
WO2023049438A1 (en) Grk2 inhibitors and uses thereof
CA3173819A1 (en) Small molecule degraders of phosphatidylinositol-5-phosphate 4-kinase type 2 and uses thereof
HK1228196A1 (en) Dihydropteridinone derivatives and uses thereof
HK1229329A1 (en) Diaminopyrimidine benzenesulfone derivatives and uses thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)